Scheiermann Julia, Klinman Dennis M
Cancer and Inflammation Program, National Cancer Institute, NIH, Frederick MD 21702, United States.
Cancer and Inflammation Program, National Cancer Institute, NIH, Frederick MD 21702, United States.
Vaccine. 2014 Nov 12;32(48):6377-89. doi: 10.1016/j.vaccine.2014.06.065. Epub 2014 Jun 24.
Synthetic oligonucleotides (ODN) that express unmethylated "CpG motifs" trigger cells that express Toll-like receptor 9. In humans this includes plasmacytoid dendritic cells and B cells. CpG ODN induce an innate immune response characterized by the production of Th1 and pro-inflammatory cytokines. Their utility as vaccine adjuvants was evaluated in a number of clinical trials. Results indicate that CpG ODN improve antigen presentation and the generation of vaccine-specific cellular and humoral responses. This work provides an up-to-date overview of the utility of CpG ODN as adjuvants for vaccines targeting infectious agents and cancer.
表达未甲基化“CpG基序”的合成寡核苷酸（ODN）可激活表达Toll样受体9的细胞。在人类中，这包括浆细胞样树突状细胞和B细胞。CpG ODN可诱导以Th1和促炎细胞因子产生为特征的先天免疫反应。在多项临床试验中评估了它们作为疫苗佐剂的效用。结果表明，CpG ODN可改善抗原呈递以及疫苗特异性细胞和体液反应的产生。这项工作提供了关于CpG ODN作为针对传染病原体和癌症的疫苗佐剂效用的最新概述。
